Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients

Nephrology

Volumn 17, Issue 7, 2012, Pages 642-649

  Zhou, Qiugen ^a   Wu, Shengjie ^a   Jiang, Jianping ^a   Tian, Jianwei ^a   Chen, Jianghua ^f   Yu, Xueqing ^c   Chen, Pingyan ^b   Mei, Changlin ^g   Xiong, Fei ^h   Shi, Wei ^d   Zhou, Wei ⁱ   Liu, Xusheng ^e   Sun, Shiren ^j   Xie, Di ^a   Liu, Jun ^a   Xu, Xin ^a   Liang, Min ^a   Hou, Fanfan ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^f ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

ⁱ 309TH HOSPITAL OF PLA   (China)

^j FOURTH MILITARY MEDICAL UNIVERSITY   (China)

more..

Author keywords

advanced oxidation protein product; continuous ambulatory peritoneal dialysis; haemodialysis; ischaemic heart disease

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; BICARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; IRON; LACTIC ACID; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; ARTIFICIAL KIDNEY; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHINA; COHORT ANALYSIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCREENING TEST; SPECTROPHOTOMETRY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ADVANCED OXIDATION PROTEIN PRODUCTS; AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MALONDIALDEHYDE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; ODDS RATIO; OXIDATIVE STRESS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SPECTROPHOTOMETRY; UP-REGULATION;

EID: 84865835355     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01640.x     Document Type: Article

References (33)

1. Levey AS, Beto JA, Coronado BE, et al,. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am. J. Kidney Dis. 1998; 32: 853-906. (Pubitemid 28516321)
2. Baber U, de Lemos JA, Khera A, et al,. Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int. 2008; 73: 615-21. (Pubitemid 351264109)
3. Longenecker JC, Coresh J, Powe NR, et al,. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J. Am. Soc. Nephrol. 2002; 13: 1918-27. (Pubitemid 34700618)
4. Siems W, Quast S, Carluccio F, et al,. Oxidative stress in cardio renal anemia syndrome: Correlations and therapeutic possibilities. Clin. Nephrol. 2003; 60 (Suppl 1): S22-S30. (Pubitemid 36889537)
5. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C,. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol. Dial. Transplant. 2003; 18: 1272-80. (Pubitemid 36826946)
6. Himmelfarb J, McMonagle E,. Manifestations of oxidant stress in uremia. Blood Purif. 2001; 19: 200-5. (Pubitemid 32041354)
7. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al,. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49: 1304-13. (Pubitemid 26166404)
8. Yang XB, Hou FF, Wu Q, et al,. Increased levels of advanced oxidation protein products are associated with atherosclerosis in chronic kidney disease. Zhonghua Nei Ke Za Zhi 2005; 44: 342-6.
9. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al,. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am. J. Kidney Dis. 2005; 45: 39-47. (Pubitemid 40038043)
10. Liu SX, Hou FF, Guo ZJ, et al,. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1156-62.
11. Guo ZJ, Niu HX, Hou FF, et al,. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid. Redox Signal. 2008; 10: 1699-712.
12. Kocak H, Gumuslu S, Sahin E, et al,. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Nephrology (Carlton) 2009; 14: 273-80.
13. Marsche G, Frank S, Hrzenjak A, et al,. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ. Res. 2009; 104: 750-7.
14. Drueke T, Witko-Sarsat V, Massy Z, et al,. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-17. (Pubitemid 35222215)
15. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al,. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J. Am. Soc. Nephrol. 2003; 14: 3270-7. (Pubitemid 37509303)
16. O'Hare A, Johansen K,. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2001; 12: 2838-47. (Pubitemid 33115433)
17. Nieminen MS, Bohm M, Cowie MR, et al,. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 2005; 26: 384-416. (Pubitemid 40283098)
18. Zhang L, Wang F, Wang L, et al,. Prevalence of chronic kidney disease in China: A cross-sectional survey. Lancet 2012; 379: 815-22.
19. Anderstam B, nn-Christin BH, Valli A, Stenvinkel P, Lindholm B, Suliman ME,. Modification of the oxidative stress biomarker AOPP assay: Application in uremic samples. Clin. Chim. Acta 2008; 393: 114-18.
20. Valli A, Suliman ME, Meert N, et al,. Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin. Chim. Acta 2007; 379: 87-94. (Pubitemid 46366973)
21. Kose FA, Sezis M, Akcicek F, Pabuccuoglu A,. Oxidative and nitrosative stress markers in patients on hemodialysis and peritoneal dialysis. Blood Purif. 2011; 32: 202-8.
22. Coskun C, Kural A, Doventas Y, et al,. Hemodialysis and protein oxidation products. Ann. N. Y. Acad. Sci. 2007; 1100: 404-8. (Pubitemid 47092679)
23. Stadtman ER, Berlett BS,. Reactive oxygen-mediated protein oxidation in aging and disease. Chem. Res. Toxicol. 1997; 10: 485-94. (Pubitemid 27217204)
24. Descamps-Latscha B, Drueke T, Witko-Sarsat V,. Dialysis-induced oxidative stress: Biological aspects, clinical consequences, and therapy. Semin. Dial. 2001; 14: 193-9. (Pubitemid 33720852)
25. Ward RA, McLeish KR,. Oxidant stress in hemodialysis patients: What are the determining factors? Artif. Organs 2003; 27: 230-6. (Pubitemid 36423478)
26. Latcha S, Hong S, Gibbons N, Kohn N, Mattana J,. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis. Nephrol. Dial. Transplant. 2008; 23: 3295-301.
27. Feldman HI, Joffe M, Robinson B, et al,. Administration of parenteral iron and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 2004; 15: 1623-32. (Pubitemid 38679688)
28. Kuo KL, Hung SC, Wei YH, Tarng DC,. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J. Am. Soc. Nephrol. 2008; 19: 1817-26.
29. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M,. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002; 162: 221-5. (Pubitemid 34327362)
30. Barsotti A, Fabbi P, Fedele M, et al,. Role of advanced oxidation protein products and Thiol ratio in patients with acute coronary syndromes. Clin. Biochem. 2011; 44: 605-11.
31. Ashfaq S, Abramson JL, Jones DP, et al,. The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults. J. Am. Coll. Cardiol. 2006; 47: 1005-11.
32. Perl J, Bargman JM,. The importance of residual kidney function for patients on dialysis: A critical review. Am. J. Kidney Dis. 2009; 53: 1068-81.
33. Hoek FJ, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT,. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol. Dial. Transplant. 2007; 22: 1633-8. (Pubitemid 47073762)